Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was: Recruiting

Sponsor:

Information provided by:

Asociación para Evitar la Ceguera en México

ClinicalTrials.gov Identifier:

NCT00418431

First received: January 3, 2007

Last updated: NA

Last verified: June 2006

History: No changes posted

Purpose

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.

The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Condition	Intervention	Phase
Central Serous Chorioretinopathy	Drug: Intravitreal injection of Bevacizumab	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment

Resource links provided by NLM:

Drug Information available for: Bevacizumab

Genetic and Rare Diseases Information Center resources: Central Serous Chorioretinopathy

U.S. FDA Resources

Further study details as provided by Asociación para Evitar la Ceguera en México:


Study Start Date:	April 2006
Estimated Study Completion Date:	August 2006

Eligibility


Ages Eligible for Study:	20 Years to 50 Years (Adult)
Sexes Eligible for Study:	All

Criteria

Inclusion Criteria

Any visual acuity.
Central serous chorioretinopathy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00418431

Contacts


Contact: Mitzy E Torres Soriano, MD	525510841400 ext 1172	retinamex@yahoo.com
Contact: Hugo Quiroz-Mercado, MD	525510841400 ext 1171	hugoquiroz@yahoo.com

Locations


Mexico
Asociacion para Evitar la Ceguera en Mexico	Recruiting
Mexico DF, DF, Mexico, 04030
Contact: Mitzy E Torres Soriano, MD 5255510841400 ext 1171 mitzytorres@yahoo.com
Sub-Investigator: Maura Abraham, MD
Sub-Investigator: Orlando Ustariz, MD
Sub-Investigator: Gerardo Garcia Aguirre
Sub-Investigator: Veronica Kon-Jara, MD
Sub-Investigator: Hugo Quiroz-Mercado, MD
Sub-Investigator: Jose L Guerrero, MD

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators


Principal Investigator:	Mitzy E Torres Soriano, MD	APEC

More Information


ClinicalTrials.gov Identifier:	NCT00418431 History of Changes
Other Study ID Numbers:	APEC-0016
Study First Received:	January 3, 2007
Last Updated:	January 3, 2007

Additional relevant MeSH terms:


Central Serous Chorioretinopathy Retinal Diseases Eye Diseases Bevacizumab Angiogenesis Inhibitors	Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents

ClinicalTrials.gov processed this record on June 23, 2017

To Top